Alumis Inc. (NASDAQ: ALMS)

Sector: Healthcare Industry: Biotechnology CIK: 0001847367
P/B 3.14
P/E -4.93
P/S 54.65
Market Cap 1.21 Bn
ROIC (Qtr) -96.33
Div Yield % 0.00
Rev 1y % (Qtr) 0.00
Total Debt (Qtr) 37.80 Mn
Debt/Equity (Qtr) 0.10

About

Stock Price Chart

Analysis

Pros

  • Healthy cash reserves of 65.26M provide 14.79x coverage of short-term debt 4.41M, demonstrating strong liquidity position and minimal refinancing risk.
  • Strong tangible asset base of 437.06M provides 11.56x coverage of total debt 37.80M, indicating robust asset backing and low credit risk.
  • Tangible assets of 437.06M provide exceptional 224.82x coverage of deferred revenue 1.94M, showing strong service capability backing.
  • Short-term investments of 312.47M provide solid 5.54x coverage of other current liabilities 56.45M, indicating strong liquidity.
  • Tangible assets of 437.06M provide robust 7.74x coverage of other current liabilities 56.45M, indicating strong asset backing.

Cons

  • Operating cash flow of (372.38M) barely covers its investment activities of 223.81M, with a coverage ratio of -1.66, indicating heavy reliance on external financing for growth which may not be sustainable in a tighter credit environment.
  • Investment activities of 223.81M provide weak support for R&D spending of 390.42M, which is 0.57x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • Cash reserves of 65.26M provide limited coverage of acquisition spending of 49.74M, which is 1.31x, suggesting aggressive expansion might strain liquidity if market conditions deteriorate.
  • Operating cash flow of (372.38M) provides insufficient coverage of deferred revenue obligations of 1.94M, which is -191.55x, raising concerns about future service delivery capabilities.
  • Short-term investments of 312.47M significantly exceed cash reserves of 65.26M, which is 4.79x, indicating potentially excessive yield-seeking behavior at the expense of liquidity.

Peer Comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 SMMT Summit Therapeutics Inc. 1,349.40 Bn -1,464.17 0.00 0.01 Bn
2 ONC BeOne Medicines Ltd. 437.43 Bn 6,381.20 87.97 1.90 Bn
3 VRTX Vertex Pharmaceuticals Inc / Ma 116.09 Bn 31.59 9.90 1.83 Bn
4 REGN Regeneron Pharmaceuticals, Inc. 78.10 Bn 17.06 5.48 2.71 Bn
5 ALNY Alnylam Pharmaceuticals, Inc. 55.87 Bn 1,282.42 17.40 3.21 Bn
6 ARGX Argenx Se 52.85 Bn 35.08 27,559.65 -
7 BNTC Benitec Biopharma Inc. 41.75 Bn -998.33 0.00 0.00 Bn
8 INSM INSMED Inc 37.80 Bn -31.93 84.56 0.74 Bn

Industry Comparisons

Current Valuation

Metric Value Industry Percentile
EV to Assets 2.24 12.31
EV to Cash from Ops. -2.94 23.25
EV to Debt 28.99 738.44
EV to EBIT -4.32 -9.16
EV to EBITDA -2.43 6.95
EV to Free Cash Flow [EV/FCF] -2.93 21.90
EV to Market Cap 0.91 65.67
EV to Revenue 49.53 227.32
Price to Book Value [P/B] 3.14 22.34
Price to Earnings [P/E] -4.93 -11.77

Dividend Metrics

Metric Value Industry Percentile
Dividend Coverage Ratio 0.00 -11.94
Dividend Payout Ratio % 0.00 0.16
Dividend per Basic Share 0.00 0.01
FCF Dividend Payout Ratio % 0.00 -0.14
Interest Coverage 0.00 841.00

Growth Metrics

Metric Value Industry Percentile
Capex Growth (1y) % 60.44 -27.13
Cash and Equivalents Growth (1y) % -69.42 734.65
Dividend Growth (1y) % 0.00 0.01
EBIAT Growth (1y) % -2.67 -46.93
EBITDA Growth (1y) % -88.74 -1.68
EBIT Growth (1y) % -6.26 -56.45
EBT Growth (1y) % -6.26 -12.70
EPS Growth (1y) % 96.30 -28.31
FCF Growth (1y) % -72.38 -31.90
Gross Profit Growth (1y) % 0.00 226.84

Liquidity Ratios

Metric Value Industry Percentile
Asset Utilization Ratio 0.05 0.14
Cash Payout Ratio 0.00 0.00
Cash Ratio 1.00 3.85
Current Ratio 6.01 7.27
Debt to Equity Ratio 0.10 0.40
Interest Cover Ratio 0.00 841.00
Times Interest Earned 0.00 841.00

Profitability

Metric Value Industry Percentile
EBITDA Margin % -1,126.00 -18,234.31
EBIT Margin % -1,146.94 -18,580.80
EBT Margin % -1,146.94 -19,488.74
Gross Margin % 100.00 -7.59
Net Profit Margin % -1,108.20 -19,439.22